Menu
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.
Price
Target price
€6.14

€6.14

0.320%
0.019
0.320%
€19.65
 
21.07.25 / Tradegate WKN: A2PKMZ / Symbol: NVAX / Name: Novavax / Stock / Biotechnology & Medical Research / Small Cap /
Please give a prediction to see the opinions of the community
sharewise uses Wisdom of crowds to gather information regarding a security. Wisdom of crowds works best if you do not see the predictions of others before giving your estimate. Please click one button to see how the community sees this security.
Your prediction

Novavax Inc. Stock

The Novavax Inc. stock is trending slightly upwards today, with an increase of €0.019 (0.320%) compared to yesterday's price.
Currently there is a rather positive sentiment for Novavax Inc. with 10 Buy predictions and 3 Sell predictions.
Based on the current price of 6.14 € the target price of 19 € shows a potential of 209.55% for Novavax Inc. which would more than double the current price.
For the coming years our community has positive and negative things to say abot the Novavax Inc. stock. Criterium "Worthwhile Investment for the next years" gathered the most positive votes but regarding "Expected dividend yield" there were negative voices in the community.

Pros and Cons of Novavax Inc. in the next few years

Pros
?
G***** c******* t* c**********
?
B****
?
W********* I********* f** t** n*** y****
Cons
?
S********** s********
?
M***** P*******
?
C******** o* t** e**********
Tell us your opinion to access the 'Wisdom of the Crowds'

Performance of Novavax Inc. vs. its peers

Security Change(%) 1w 1m 1y YTD 3y 5y
Novavax Inc. 0.320% 2.676% 10.178% -51.806% -22.037% -89.364% -94.972%
Krystal Biotech -0.750% -0.079% 10.222% -32.264% -16.754% 73.562% -
Ardelyx Inc. -0.160% -4.307% 22.352% -25.503% -23.927% 428.695% -30.697%
Evolus Inc - -3.106% -1.887% -27.778% -25.714% -40.909% 181.284%

sharewise BeanCounterBot

The analysis provided is generated by an artificial intelligence system and is provided for informational purposes only. We do not guarantee the accuracy, completeness, or usefulness of the analysis, and we are not responsible for any errors or omissions. Use of the analysis is at your own risk.
Last updated at 2023-04-30

General Impression

The financials of Novavax, a Biotechnology & Medical Research company with US symbol NVAX, paint a mixed picture. Over the past few years, the company has reported a significant increase in its revenue and total assets. However, its net income has consistently been in the negative, and it has faced challenges in maintaining a positive net working capital and managing its liabilities.

Detailed Analysis

Comments

Prediction Sell
Perf. (%) 4.82%
Target price 5.194
Change
Ends at 17.06.26

Novavax, Inc. (NASDAQ: NVAX) is now covered by analysts at Citigroup Inc.. They set a "sell" rating and a $6.00 price target on the stock.
Ratings data for NVAX provided by MarketBeat
Show more

Novavax, Inc. (NASDAQ: NVAX) had its "buy" rating re-affirmed by analysts at B. Riley.
Ratings data for NVAX provided by MarketBeat
Show more

Prediction Sell
Perf. (%) 12.58%
Target price 6.242
Change
Ends at 09.05.26

Novavax, Inc. (NASDAQ: NVAX) had its price target lowered by analysts at JPMorgan Chase & Co. from $9.00 to $7.00. They now have an "underweight" rating on the stock.
Ratings data for NVAX provided by MarketBeat
Show more

News

2 Beaten-Down Stocks That Haven't Hit Rock Bottom Yet: https://g.foolcdn.com/editorial/images/824198/person-working-in-a-cannabis-facility.jpg
2 Beaten-Down Stocks That Haven't Hit Rock Bottom Yet

Buying shares of beaten-down companies only makes sense if there are good reasons to expect them to bounce back. If that's not the case, stocks that may look cheap and attractive aren't actually so

Novavax Stock: FDA Approval Triggers Financial Windfall
Novavax Stock: FDA Approval Triggers Financial Windfall

The U.S. Food and Drug Administration has granted full approval (Biologics License Application) for Novavax's COVID-19 vaccine Nuvaxovid, marking a significant breakthrough for the biotech company

2 Beaten-Down Stocks That Still Aren't Worth Buying
2 Beaten-Down Stocks That Still Aren't Worth Buying

President Trump's trade policies are sending many stocks that were performing well in the wrong direction and exacerbating things for others that were already struggling. So, the time seems ripe for